Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of December 2017, with a report date of December 26, 2017. The filing discloses the resignation of the Chief Financial Officer and the execution of a separation agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive personnel changes and associated compensation terms.
Material Changes
The primary material change is the departure of Josh Blacher, who served as Chief Financial Officer since May 2017. He resigned effective December 19, 2017, following a mutually amicable separation agreement.
Guidance, Outlook, and Management Commentary
Management commentary indicates the Company is actively searching for a new Chief Financial Officer. Mr. Blacher will support an orderly transition of responsibilities. The filing does not contain financial guidance, outlook, or discussion of risks beyond the leadership transition.
Separation Agreement Terms
- Severance: Three months' salary through the end of the notice period.
- Bonus: A bonus equal to two months of salary.
- Equity: All outstanding options to purchase 47,500 American Depositary Shares are deemed fully vested as of the Effective Date.
- Exercise Period: Vested options may be exercised within 90 days (by June 19, 2018).
Investor Verification Checklist
- Confirm the timeline for the appointment of a new Chief Financial Officer.
- Verify the total cash compensation cost associated with the separation agreement.
- Monitor the exercise status of the 47,500 vested options granted to the departing CFO.
- Review subsequent filings for any impact on internal controls or financial reporting due to the CFO vacancy.